Literature DB >> 18054677

Overcoming treatment challenges in advanced breast cancer.

Barbara Harkins1, Charles E Geyer.   

Abstract

OBJECTIVES: To describe new clinical findings, efficacy, and safety regarding the use of targeted agents in the treatment of HER2-positive metastatic breast cancer. DATA SOURCES: Published research articles, abstracts, and clinical experience.
CONCLUSION: HER2-positive cases of breast cancer tend to be more aggressive and more likely to become resistant to therapy than HER2-negative tumors. The current standard approach to patients with HER2-positive metastatic breast cancer includes the use of trastuzumab. Because cellular mechanisms can arise that can block the efficacy of this approach (and result in clinical resistance), recent research has led to the development of lapatinib, a targeted therapy that can act on HER2 inside the cell to disrupt the signaling pathways thought to be part of tumorigenic mechanisms. IMPLICATIONS FOR NURSING PRACTICE: Oncology nurses should be aware of the treatment strategies for HER2-positive metastatic breast cancer and its limitations, which is essential for providing optimal nursing care.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18054677     DOI: 10.1016/j.soncn.2007.10.003

Source DB:  PubMed          Journal:  Semin Oncol Nurs        ISSN: 0749-2081            Impact factor:   2.315


  3 in total

1.  Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers.

Authors:  Min Yao; Elaine Yu; Vincent Staggs; Fang Fan; Nikki Cheng
Journal:  Mod Pathol       Date:  2016-04-29       Impact factor: 7.842

2.  First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines.

Authors:  Senthilmurugan Ramalingam; Lalji Gediya; Andrew K Kwegyir-Afful; Vidya P Ramamurthy; Puranik Purushottamachar; Hannah Mbatia; Vincent C O Njar
Journal:  Oncotarget       Date:  2014-01-30

3.  Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins.

Authors:  An Zou; Diana Lambert; Henry Yeh; Ken Yasukawa; Fariba Behbod; Fang Fan; Nikki Cheng
Journal:  BMC Cancer       Date:  2014-10-24       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.